What Pre-Operative Assessment Protocols Should Clinics Follow Before Performing Facial Fractional Laser Resurfacing Treatments? Essential Safety Checklist

Before facial fractional laser resurfacing, clinics should complete a structured risk assessment, physical examination, medication review, and informed-consent process. The assessment should document skin phototype, photodamage, scar characteristics, HSV history, abnormal scarring history, eyelid laxity when relevant, prior procedures, medical conditions, medications, and allergies. Treatment should proceed only after the clinician has assessed infection, pigmentation, wound-healing, and ectropion risks and established an individualized plan.

The safest protocol is not simply a checklist of contraindications. It is a documented baseline assessment that matches laser type, treatment depth, anatomical site, and patient risk factors with appropriate preventive measures.

Establish Whether the Patient Is an Appropriate Candidate

Identify the treatment type and treatment goal

The clinician should record whether the planned treatment is non-ablative fractional resurfacing (NAFR) or ablative fractional resurfacing (AFR), and whether the goal is scar remodeling, photodamage reduction, dyspigmentation improvement, or texture correction.

The expected degree of improvement, number of sessions, recovery period, and limitations should be explained before treatment. Fractional resurfacing can improve selected scars and photodamage, but it cannot guarantee complete scar removal or uniform results.

Assess skin phototype and pigmentation risk

Document the patient’s Fitzpatrick skin type and baseline tendency toward hyperpigmentation or hypopigmentation. Darker skin types, particularly Fitzpatrick IV–VI, require careful consideration because post-inflammatory hyperpigmentation may be more likely after ablative treatment.

The clinic should also document recent sun exposure, tanning, and the patient’s ability to comply with strict sun avoidance after treatment. Elective treatment may need to be postponed if the skin is recently tanned, sunburned, or inflamed.

Examine the treatment area

Inspect the proposed treatment site for active infection, open wounds, dermatitis, suspicious lesions, or possible skin cancer. Treatment should not proceed over a clinically suspicious or actively infected area until it has been appropriately evaluated and managed.

The examination should establish a clear baseline for erythema, dyspigmentation, texture, and surface irregularity.

Document Scar and Photodamage Characteristics

Record scar morphology

For scar treatments, document each scar’s thickness, pliability, erythema, pigmentation, elevation, depression, and restriction. Residual erosion or poor epithelial integrity should also be noted.

These features help determine whether fractional resurfacing is appropriate and provide a meaningful baseline for later comparison.

Capture standardized photographs

High-quality, standardized pre-operative photographs should be taken with consistent lighting, positioning, and camera distance. Include close-up views when assessing scars or the periorbital region.

Photographs support treatment planning, informed consent, outcome assessment, and documentation of any pre-existing asymmetry or pigmentation.

Screen for Medical and Procedural Risk Factors

Ask specifically about HSV

A history of oral or facial herpes simplex virus (HSV) must be documented. Facial resurfacing can reactivate HSV, and prophylactic antiviral therapy is strongly recommended for patients with a relevant history undergoing facial AFR or NAFR.

The medication, timing, and duration should follow the clinician’s protocol and applicable local guidance. Patients should also be asked about recent outbreaks or active lesions; active infection generally requires postponement until resolved.

Document abnormal scarring history

Ask about personal and, where clinically relevant, family history of hypertrophic scars or keloids. This is particularly important before high-energy ablative passes, which may carry greater wound-healing and scarring risk.

The clinician should also document prior reactions to surgery, trauma, cosmetic procedures, or laser treatments.

Review previous procedures and eyelid surgery

Record prior eyelid, facial, cosmetic, or reconstructive surgery. Previous procedures may alter anatomy, skin tension, eyelid support, sensation, or healing behavior.

Patients with prior periorbital surgery require especially careful evaluation before treatment around the eyelids.

Review medical conditions, medications, and allergies

The history should include conditions and medications that could affect healing, infection risk, bleeding, pigmentation, or anesthesia safety. Include prescription drugs, over-the-counter products, supplements, and herbal medicines.

Document allergies and previous reactions to anesthetics, antivirals, antibiotics, antiseptics, adhesives, and topical products.

Verify isotretinoin exposure

Ask specifically about current or recent oral isotretinoin use. The supplied clinical references identify a minimum six-month interval after completing isotretinoin before ablative resurfacing, while some protocols use a longer interval, such as 6–12 months.

Because guidance may vary by procedure and jurisdiction, the treating clinician should apply the current local protocol and document the rationale for proceeding.

Perform the Periorbital Safety Assessment

Conduct the eyelid snap test

For planned periorbital treatment, perform and document an eyelid snap test to assess lower-eyelid elasticity. The examination should also check for scleral show, lid lag, pre-existing ectropion, and other signs of eyelid laxity.

Reduced elasticity increases concern for post-procedure eyelid malposition, including ectropion. Treatment parameters and candidacy should be reconsidered when baseline support is poor.

Plan ocular protection in advance

The pre-operative plan must specify appropriate ocular protection. Internal metallic ocular shields are required when treating eyelid skin, while wavelength-appropriate external protection is used for other facial treatment areas.

Ocular protection should be selected and applied by trained personnel according to the device manufacturer’s instructions and the treatment location.

Address Infection, Pigmentation, and Barrier Risks

Plan antiviral prophylaxis

For patients with a history of facial or oral HSV, prescribe antiviral prophylaxis according to the clinic’s established protocol. Antiviral coverage is especially important for ablative resurfacing because the procedure disrupts the epidermal barrier.

Protocols differ in drug choice, start time, and duration. The patient should receive clear written instructions and understand which symptoms require urgent contact.

Determine whether antibiotics are appropriate

Routine antibiotics are not generally required for non-ablative fractional resurfacing. For extensive ablative treatment, some protocols use systemic broad-spectrum antibiotic coverage, particularly when treating large areas or when patient-specific infection risks are present.

Antibiotic use should be based on the procedure, clinical risk, local policy, and antimicrobial-stewardship principles rather than applied automatically to every patient. MRSA coverage may be considered for traditional ablative or AFR procedures when risk factors or local epidemiology justify it.

Plan pigmentation prevention

For patients at increased risk of post-inflammatory hyperpigmentation, particularly darker skin types, the clinician may consider a pre-treatment pigment-control regimen. References describe agents such as hydroquinone, kojic acid, or azelaic acid used for approximately 1–2 months before ablative resurfacing.

This should be individualized because topical agents can themselves cause irritation or dermatitis. Treatment should not proceed over actively irritated or sensitized skin.

Stop potentially irritating topical products

Topical retinoids, exfoliants, and other irritating products are commonly stopped before treatment; the supplementary protocols specify approximately two weeks for topical retinoids and exfoliants.

The exact interval should reflect the product, treatment intensity, and patient skin condition. The patient should receive a written list of products to stop and products that may be continued.

Complete Consultation and Informed Consent

Set realistic expectations

The consultation should explain expected improvement, likely number of treatments, downtime, discomfort, edema, erythema, crusting, pigment changes, infection, HSV reactivation, scarring, and the possibility of incomplete or uneven results.

Patients should understand that fractional treatment creates microscopic treatment zones while leaving surrounding skin intact, but recovery and complication risk still depend on treatment depth, density, location, and individual healing.

Obtain written consent

Written informed consent should confirm that the clinician discussed:

The treatment objective and alternatives.
The planned laser type, anatomical areas, and expected recovery.
Potential complications, including infection, HSV reactivation, pigment alteration, scarring, and eyelid malposition.
The patient’s responsibilities regarding medication use, sun avoidance, wound care, and follow-up.

Consent should be obtained after the patient has had an opportunity to ask questions, not merely presented immediately before treatment.

Confirm patient readiness

Before starting, confirm that the patient understands pre- and post-treatment instructions, has disclosed all relevant medications and medical conditions, and can comply with sun protection and follow-up requirements.

Treatment should be postponed when the patient has active infection, significant dermatitis, recent tanning or sunburn, incomplete medication disclosure, or unrealistic expectations that cannot be resolved through counseling.

Understanding the Trade-offs

More aggressive treatment can increase risk

Higher-energy ablative passes and greater treatment density may provide more substantial resurfacing, but they also increase barrier disruption, downtime, infection risk, pigment alteration, and abnormal scarring risk.

The appropriate approach is the lowest treatment intensity that reasonably addresses the clinical goal, particularly in high-risk skin types or anatomically sensitive areas.

Prophylaxis is not risk elimination

Antivirals reduce the risk of HSV reactivation but do not eliminate it. Similarly, pigment-control products and sun avoidance reduce pigmentation risk but cannot guarantee that post-inflammatory hyperpigmentation will not occur.

Patients should be told the purpose and limits of each preventive measure.

Blanket protocols can be inappropriate

A universal antibiotic or medication regimen may expose low-risk patients to unnecessary adverse effects and may not address the actual source of risk. Conversely, failing to use prophylaxis in a clearly susceptible patient can create avoidable complications.

The clinic should use a written protocol that still allows clinician-directed adjustment for treatment depth, surface area, anatomy, and patient history.

Making the Right Choice for Your Goal

The final pre-operative record should show not only that questions were asked, but how the findings changed the treatment plan.

If your primary focus is patient safety: Complete HSV, abnormal-scar, medication, allergy, medical-history, and periorbital elasticity screening before selecting treatment settings.
If your primary focus is scar improvement: Document scar thickness, pliability, erythema, pigmentation, restriction, and standardized baseline photographs.
If your primary focus is periorbital treatment: Perform and record the eyelid snap test, assess scleral show and lid lag, and establish an ocular-protection plan.
If your primary focus is minimizing pigmentation complications: Record phototype and sun exposure, postpone treatment on recently tanned or irritated skin, and consider individualized pre-treatment pigment control.
If your primary focus is infection prevention: Screen for active infection and HSV, use antiviral prophylaxis when indicated, and reserve antibiotic coverage for appropriate ablative or higher-risk situations.

A disciplined pre-operative assessment turns fractional laser resurfacing from a device procedure into a controlled, patient-specific treatment plan.

Summary Table:

Assessment Area	Key Components	Purpose
Patient Candidacy	Skin type, treatment goals, sun exposure	Determine suitability and risks
Skin Examination	Active infections, lesions, baseline characteristics	Avoid treating contraindicated areas
Scar & Photodamage	Morphology, standardized photos	Plan treatment and track outcomes
Medical History	HSV, scarring, surgeries, medications, isotretinoin	Identify risk factors
Periorbital Safety	Eyelid snap test, ocular protection	Prevent ectropion and eye injury
Infection & Pigmentation	Antiviral, antibiotic, pigment control	Minimize complications
Consent & Readiness	Expectations, written consent, compliance	Ensure informed agreement and adherence

Ensure your patients receive the highest standard of care with BELIS's advanced fractional laser systems. Our FDA-approved devices, including CO2 and Erbium lasers, are designed for safety and efficacy in clinical settings. Partner with BELIS to access cutting-edge technology, comprehensive training, and dedicated support. Contact us today to learn more about how our solutions can enhance your practice and patient outcomes. [Schedule a consultation] (#ContactForm)